{"id":7985,"date":"2025-09-05T11:14:23","date_gmt":"2025-09-05T11:14:23","guid":{"rendered":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/?p=7985"},"modified":"2025-09-05T11:17:59","modified_gmt":"2025-09-05T11:17:59","slug":"obviousness-synergy-and-enablement-in-biologic-formulations","status":"publish","type":"post","link":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/","title":{"rendered":"Obviousness, Synergy, and Enablement in Biologic Formulations"},"content":{"rendered":"<section>\n<h2><span class=\"ez-toc-section\" id=\"Background\"><\/span>Background<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"small\">Amgen, a U.S.-based company that makes medicines from natural substances like proteins, created a medicine called <strong>romiplostim<\/strong>, sold as <em>Nplate<\/em>. This medicine mimics a natural body signal (a hormone called thrombopoietin, or <strong>TPO<\/strong>) that tells your body to produce platelets \u2014 tiny components in your blood that help stop bleeding by forming clots. It\u2019s vital for people with a condition called <strong>immune thrombocytopenic purpura (ITP)<\/strong>, where the body mistakenly attacks its own platelets, causing low counts and bleeding risks.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #0c0c0c;color:#0c0c0c\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #0c0c0c;color:#0c0c0c\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Background\" >Background<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Patent_Office_Proceedings\" >Patent Office Proceedings<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#The_Core_Dispute\" >The Core Dispute<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Courts_Reasoning\" >Court\u2019s Reasoning<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Rejection_under_Section_3d_Mere_Use_of_a_Known_Substance\" >Rejection under Section 3(d): Mere Use of a Known Substance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Rejection_under_Section_3e_Mere_Admixture_Without_Synergy\" >Rejection under Section 3(e): Mere Admixture Without Synergy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#3_Lack_of_Inventive_Step_under_Section_21ja\" >3. Lack of Inventive Step under Section 2(1)(ja)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Insufficiency_under_Section_104\" >Insufficiency under Section 10(4)<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Final_Decision\" >Final Decision<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#Disclaimer_Authorship\" >Disclaimer &amp; Authorship<\/a><\/li><\/ul><\/nav><\/div>\n\n<p class=\"small\">Medicines like romiplostim, made from living sources, are delicate. They can break down or clump together if not handled carefully, much like milk curdling outside the fridge. To solve this, Amgen developed a way to freeze-dry the medicine (a process called <strong>lyophilization<\/strong>), turning it into a stable powder that\u2019s easier to store, ship, and mix with water for use later.<\/p>\n<p class=\"small\">Amgen applied for a patent in India on <strong>9 September 2008<\/strong>, under application number <strong>5857\/CHENP\/2008<\/strong>, titled \u201c<em>Lyophilized Therapeutic Peptibody Formulations<\/em>.\u201d They described a specific dry mix: the main medicine (romiplostim, structured as <strong>Formula V<\/strong> in their papers) showing the mix stays stable, doesn\u2019t clump, and that the additives work together better than alone.<\/p>\n<\/section>\n<section>\n<h2><span class=\"ez-toc-section\" id=\"Patent_Office_Proceedings\"><\/span>Patent Office Proceedings<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"small\">Amgen asked the Indian Patent Office to review their application. On <strong>20 July 2013<\/strong>, the office issued a First Examination Report (FER), raising objections under Sections <strong>3(d)<\/strong>, <strong>3(e)<\/strong>, and <strong>2(1)(ja)<\/strong> of the Patents Act, 1970. These rules block patents for things like reusing known methods, simple mixes without special effects, or ideas that aren\u2019t creative enough compared to existing documents (called prior arts <em>D1\u2013D6<\/em>.).<\/p>\n<p class=\"small\">Amgen responded, narrowing their claims to focus on <strong>Formula V<\/strong>, which covered 52 slight variations of the main medicine part. Then, Intas Pharmaceuticals Limited objected on <strong>18 July 2016<\/strong>, under Sections 25(1)(e) (obviousness), 25(1)(f) (not an invention), and 25(1)(g) (incomplete explanation).<\/p>\n<p class=\"small\">After hearings, the Assistant Controller rejected the application on <strong>31 March 2023<\/strong>, citing Section <strong>2(1)(ja)<\/strong> (not creative), Section <strong>3(d)<\/strong> (reusing known methods), Section <strong>3(e)<\/strong> (simple mix), and Section <strong>10(4)<\/strong> (not fully explained). They pointed to prior arts and said there was no proof of real improvement.<\/p>\n<p class=\"small\">Amgen appealed to the Madras High Court under Section <strong>117A<\/strong> of the Patents Act, 1970, which allows challenging patent rejections.<\/p>\n<\/section>\n<section>\n<h2><span class=\"ez-toc-section\" id=\"The_Core_Dispute\"><\/span>The Core Dispute<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"small\">The core issue was whether Amgen\u2019s dry medicine mix qualified as a patentable invention under the Indian Patents Act, 1970. Patents are granted only for ideas that are <strong>new<\/strong>, involve an <strong>inventive step<\/strong>, and can be used <strong>industrially<\/strong>, but certain rules block patents for specific cases. The court had to answer four key questions:<\/p>\n<ol class=\"small\">\n<li><strong>Section 3(d):<\/strong> Did Amgen\u2019s method for making the dry mix just reuse an old, known process without adding anything new?<\/li>\n<li><strong>Section 3(e):<\/strong> Was the mix just a simple blend of known ingredients that don\u2019t work together in a special way to create a better result?<\/li>\n<li><strong>Section 2(1)(ja):<\/strong> Would an average expert in medicine-making (called a person skilled in the art, or <em>PSITA<\/em>) find this mix obvious by looking at old documents (prior arts <em>D1\u2013D5<\/em>)?<\/li>\n<li><strong>Section 10(4):<\/strong> Did Amgen explain their idea fully and clearly in their application, especially since it could apply to 52 variations, but they only tested one?<\/li>\n<\/ol>\n<p class=\"small\">Amgen argued their mix was unique for their medicine, their tests showed the ingredients teamed up to prevent spoiling and clumping, picking the right additives and amounts was a creative challenge, and their explanation was enough with one example representing the group. The opponents (the Patent Office and Intas) countered that it was obvious by combining old documents, just a simple mix, and not fully explained for all variations.<\/p>\n<\/section>\n<section>\n<h2><span class=\"ez-toc-section\" id=\"Courts_Reasoning\"><\/span>Court\u2019s Reasoning<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"small\">The Hon&#8217;ble judge began by explaining in simple terms how medicines from living sources are fragile, need injections (not pills), and why choosing additives is like solving a puzzle\u2014each medicine needs its own perfect recipe. Below is a summary of how the court handled each legal issue, keeping the law\u2019s language intact.<\/p>\n<ol type=\"i\">\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Rejection_under_Section_3d_Mere_Use_of_a_Known_Substance\"><\/span>Rejection under Section 3(d): Mere Use of a Known Substance<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p class=\"small\">Section 3(d) of the Patents Act, 1970, says you can\u2019t patent \u201cthe mere use of a known substance\u201d unless it creates a new product or uses a new ingredient. The Assistant Controller rejected claim 9 (the method for preparing and drying the mix with specific additives and amounts), saying it was just using the old freeze-drying process, pointing to prior art D4 (which mentioned the medicine) and general knowledge.<\/p>\n<p class=\"small\">The court examined claim 9 and disagreed. It found no prior art showed exactly how to dry this specific medicine with these additives in these amounts. Prior art D4 mentioned freeze-drying vaguely, saying compositions \u201cmay be in dried powder, such as lyophilized form,\u201d but gave no steps or details. Prior art D5 described drying a different substance but had no method steps. The court concluded that claim 9\u2019s process, with its specific additives and amounts, wasn\u2019t just reusing a known method\u2014it added something new. Thus, the rejection under Section 3(d) was not sustainable.\n<\/p>\n<\/li>\n<li>\n<h3><span class=\"ez-toc-section\" id=\"Rejection_under_Section_3e_Mere_Admixture_Without_Synergy\"><\/span>Rejection under Section 3(e): Mere Admixture Without Synergy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p class=\"small\">Section 3(e) blocks patents for \u201ca substance obtained by a mere admixture resulting only in the aggregation of the properties of the components thereof.\u201d This means a mix where the parts just do their usual jobs, adding up normally, isn\u2019t patentable. The mix must show <em>synergy<\/em>\u2014where the whole is better than the sum of the parts, like ingredients in a cake that create a unique flavor together.<\/p>\n<\/li>\n<\/ol>\n<p class=\"small\">The Assistant Controller said Amgen\u2019s mix was a simple blend because they didn\u2019t provide data comparing the mix before and after drying to prove better stability. The court rejected this, saying Section 3(e) doesn\u2019t always require before-and-after drying data. The goal is to show the ingredients interact to produce a result greater than their individual effects. Amgen\u2019s tests (Tables 39\u201341) did this:<\/p>\n<ul class=\"small\">\n<li><strong>Table 39:<\/strong> Showed that using at least 1.5% sucrose (a stabilizer) reduced chemical breakdown at high temperatures, while less sucrose led to more spoiling. High amounts of another additive (mannitol) alone didn\u2019t help.<\/li>\n<li><strong>Tables 40 and 41:<\/strong> Showed that adding polysorbate-20 (a clumping preventer) kept clumping under 0.1%, compared to much higher clumping without it. Tests used different medicine amounts (0.5 mg\/mL and 0.3 mg\/mL), but this didn\u2019t matter for proving the additive\u2019s teamwork.<\/li>\n<\/ul>\n<p class=\"small\">The Controller argued the different amounts made the data weak, but the court said the tests\u2019 purpose was to show synergy (polysorbate-20\u2019s effect on clumping), not to compare amounts. Unlike prior art D3, which aimed to increase substance concentration, Amgen\u2019s goal was stability, so before-and-after drying data wasn\u2019t needed. The court found clear synergy, setting aside the Section 3(e) rejection.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Lack_of_Inventive_Step_under_Section_21ja\"><\/span>3. Lack of Inventive Step under Section 2(1)(ja)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p class=\"small\">Section 2(1)(ja) requires an \u201cinventive step\u201d\u2014a feature that makes the invention not obvious to a person skilled in the art (PSITA), defined as an average medicine-making expert with common knowledge but no extraordinary creativity. The Controller said the mix was obvious based on prior arts D1\u2013D5 (D6 and D7 weren\u2019t used in the appeal).<\/p>\n<p class=\"small\">The court played the role of the PSITA and analyzed each prior art:<\/p>\n<ul class=\"small\">\n<li><strong>D1\u2013D3:<\/strong> D1 (Amgen\u2019s work on a different binder) didn\u2019t mention this medicine or drying. D2 (Amgen\u2019s modified proteins) discussed combining parts for longer life but not drying. D3 focused on drying to increase concentration, not stability, so a PSITA wouldn\u2019t apply it here. These didn\u2019t make the mix obvious alone or together.<\/li>\n<li><strong>D4:<\/strong> Amgen\u2019s own document on the same medicine (including the exact structure, SEQ ID 1017) for ITP treatment. It mentioned dry forms and additives like sucrose but vaguely, without specific drying steps, additive types, or amounts. A PSITA couldn\u2019t reach Amgen\u2019s mix from D4 or D1\u2013D4.<\/li>\n<li><strong>D5:<\/strong> Described drying a different substance (IL-12, for cancer) with similar additives: 2% sucrose, 4.15% mannitol, 0.02% polysorbate-20, and a buffer at pH 5.6. The Controller suggested combining D4 and D5, but the court disagreed. The substances were different (IL-12 is a paired helper for cancer; romiplostim is a fused piece for platelets). D4 didn\u2019t suggest looking at D5. Scientific literature showed 6\u201316 options for each additive type, making selection a complex puzzle with thousands of combinations. No standard recipe exists, and a common clumping preventer (polysorbate-80) differed from Amgen\u2019s choice (polysorbate-20).<\/li>\n<\/ul>\n<p class=\"small\">The court concluded that choosing these additives and exact amounts for this medicine wasn\u2019t obvious \u2014 it took creative work. The Section 2(1)(ja) rejection was unsustainable.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Insufficiency_under_Section_104\"><\/span>Insufficiency under Section 10(4)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p class=\"small\">Section 10(4) requires a patent application to fully and clearly describe the invention, including the best method known, so others can recreate it. Amgen\u2019s Formula V covered 52 variations of the medicine\u2019s core part, but tests (Tables 39\u201341) only showed one (SEQ ID 1017). The court noted that these variations differ in structure, affecting how they behave. Without guidance for the other 51, the application didn\u2019t fully enable them. However, the tested variation (and its close family, SEQ ID 1012\u20131017) was well-explained. The court partly upheld this objection, narrowing the patent to cover only the tested variation (SEQ ID NO. 459).<\/p>\n<\/section>\n<section>\n<h2><span class=\"ez-toc-section\" id=\"Final_Decision\"><\/span>Final Decision<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"small\">The Madras High Court allowed Amgen\u2019s appeal under Section 117A, setting aside the Assistant Controller\u2019s rejection order dated <strong>31 March 2023<\/strong>. The patent application was sent back for approval, but with amendment. This ruling is a milestone for medicine patents in India. It shows that courts will protect creative solutions in complex fields like biologics if they demonstrate real teamwork between ingredients and aren\u2019t obvious combinations of old ideas. However, inventors must fully explain their work, especially for broad claims with many variations.<\/p>\n<div class=\"case-meta small\"><strong>Case Title:<\/strong> Amgen Inc. Vs. The Assistant Controller of Patents and Designs<br \/>\n<strong>Date of order:<\/strong> 22.08.2025<br \/>\n<strong>Case Number:<\/strong> CMA (PT) No.28 of 2023<br \/>\n<strong>Neutral Citation:<\/strong> 2025:MHC:2096<br \/>\n<strong>Name of Court:<\/strong> High Court of Judicature at Madras<br \/>\n<strong>Name of Judge:<\/strong> The Hon&#8217;ble Mr. Justice Senthilkumar Ramamoorthy<\/div>\n<\/section>\n<section>\n<h2><span class=\"ez-toc-section\" id=\"Disclaimer_Authorship\"><\/span>Disclaimer &amp; Authorship<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"disclaimer\">The information shared here is intended to serve the public interest by offering insights and perspectives. However, readers are advised to exercise their own discretion when interpreting and applying this information. The content herein is subjective and may contain errors in perception, interpretation, and presentation.<\/p>\n<p class=\"small\"><strong>Written By:<\/strong> Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi<\/p>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Background Amgen, a U.S.-based company that makes medicines from natural substances like proteins, created a medicine called romiplostim, sold as Nplate. This medicine mimics a natural body signal (a hormone called thrombopoietin, or TPO) that tells your body to produce platelets \u2014 tiny components in your blood that help stop bleeding by forming clots. It\u2019s<\/p>\n","protected":false},"author":56,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"two_page_speed":[],"_jetpack_memberships_contains_paid_content":false,"_joinchat":[],"footnotes":""},"categories":[21],"tags":[28],"class_list":["post-7985","post","type-post","status-publish","format-standard","category-intellectual-property","tag-top-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6.1 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Obviousness, Synergy, and Enablement in Biologic Formulations - Legal Service India - Articles<\/title>\n<meta name=\"description\" content=\"Amgen vs Patent Office Madras HC ruling on romiplostim patent under Indian Patents Act, Sections 3(d), 3(e), 2(1)(ja) &amp; 10(4).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Obviousness, Synergy, and Enablement in Biologic Formulations\" \/>\n<meta property=\"og:description\" content=\"Amgen vs Patent Office Madras HC ruling on romiplostim patent under Indian Patents Act, Sections 3(d), 3(e), 2(1)(ja) &amp; 10(4).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/\" \/>\n<meta property=\"og:site_name\" content=\"Legal Service India - Articles\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/legalservicesind\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-05T11:14:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-05T11:17:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2025\/09\/u56-Capture-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"632\" \/>\n\t<meta property=\"og:image:height\" content=\"466\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ADVOCATE AJAY AMITABH SUMAN\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@legalserviceind\" \/>\n<meta name=\"twitter:site\" content=\"@legalserviceind\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ADVOCATE AJAY AMITABH SUMAN\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/\"},\"author\":{\"name\":\"ADVOCATE AJAY AMITABH SUMAN\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/person\\\/96ae33c2330691e5b3ccd88cf127a305\"},\"headline\":\"Obviousness, Synergy, and Enablement in Biologic Formulations\",\"datePublished\":\"2025-09-05T11:14:23+00:00\",\"dateModified\":\"2025-09-05T11:17:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/\"},\"wordCount\":1694,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#organization\"},\"keywords\":[\"Top News\"],\"articleSection\":[\"Intellectual Property\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/\",\"name\":\"Obviousness, Synergy, and Enablement in Biologic Formulations - Legal Service India - Articles\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#website\"},\"datePublished\":\"2025-09-05T11:14:23+00:00\",\"dateModified\":\"2025-09-05T11:17:59+00:00\",\"description\":\"Amgen vs Patent Office Madras HC ruling on romiplostim patent under Indian Patents Act, Sections 3(d), 3(e), 2(1)(ja) & 10(4).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/obviousness-synergy-and-enablement-in-biologic-formulations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellectual Property > Obviousness, Synergy, and Enablement in Biologic Formulations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#website\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/\",\"name\":\"Legal Service India - Law Articles\",\"description\":\"Legal Service India - Law Article Directory is the oldest in India since 2000, with thousands of article written by lawyers, law Students and Scholars on all branches of law\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#organization\",\"name\":\"Legal Service India\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo-circle-1.png\",\"contentUrl\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo-circle-1.png\",\"width\":105,\"height\":95,\"caption\":\"Legal Service India\"},\"image\":{\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/legalservicesind\",\"https:\\\/\\\/x.com\\\/legalserviceind\",\"https:\\\/\\\/www.youtube.com\\\/@LegalServiceIndia-lsi\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/#\\\/schema\\\/person\\\/96ae33c2330691e5b3ccd88cf127a305\",\"name\":\"ADVOCATE AJAY AMITABH SUMAN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\\\/\\\/www.gravatar.com\\\/avatar\\\/b894b0814afe1239db393e20da4b2e76?s=96&#038;r=g&#038;d=mm\",\"url\":\"\\\/\\\/www.gravatar.com\\\/avatar\\\/b894b0814afe1239db393e20da4b2e76?s=96&#038;r=g&#038;d=mm\",\"contentUrl\":\"\\\/\\\/www.gravatar.com\\\/avatar\\\/b894b0814afe1239db393e20da4b2e76?s=96&#038;r=g&#038;d=mm\",\"caption\":\"ADVOCATE AJAY AMITABH SUMAN\"},\"description\":\"Professional and Literary Profile Mr. Ajay Amitabh Suman, Advocate, is an alumnus of the Campus Law Centre, University of Delhi, with over 20 years of experience in IP litigation before the Delhi High Court. He currently serves as a Patent and Trademark Attorney at United &amp; United, a leading intellectual property law firm. Deeply committed to legal scholarship, he has authored more than 900 articles on intellectual property law, published on major platforms including Legal Service India, Bar &amp; Bench, Live Law, SCC Online Blog, Legal Desire, SpicyIP, among others. Beyond his legal practice, he is also an accomplished writer and poet, with over 1,500 literary works and more than 20 books published in Hindi and English. His journey reflects a unique blend of legal advocacy and creative expression, inspired by a passion for justice, knowledge, and reform.\",\"url\":\"https:\\\/\\\/www.legalserviceindia.com\\\/Legal-Articles\\\/author\\\/ajayamitabhsuman\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Obviousness, Synergy, and Enablement in Biologic Formulations - Legal Service India - Articles","description":"Amgen vs Patent Office Madras HC ruling on romiplostim patent under Indian Patents Act, Sections 3(d), 3(e), 2(1)(ja) & 10(4).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/","og_locale":"en_US","og_type":"article","og_title":"Obviousness, Synergy, and Enablement in Biologic Formulations","og_description":"Amgen vs Patent Office Madras HC ruling on romiplostim patent under Indian Patents Act, Sections 3(d), 3(e), 2(1)(ja) & 10(4).","og_url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/","og_site_name":"Legal Service India - Articles","article_publisher":"https:\/\/www.facebook.com\/legalservicesind","article_published_time":"2025-09-05T11:14:23+00:00","article_modified_time":"2025-09-05T11:17:59+00:00","og_image":[{"width":632,"height":466,"url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2025\/09\/u56-Capture-2.jpg","type":"image\/jpeg"}],"author":"ADVOCATE AJAY AMITABH SUMAN","twitter_card":"summary_large_image","twitter_creator":"@legalserviceind","twitter_site":"@legalserviceind","twitter_misc":{"Written by":"ADVOCATE AJAY AMITABH SUMAN","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#article","isPartOf":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/"},"author":{"name":"ADVOCATE AJAY AMITABH SUMAN","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/person\/96ae33c2330691e5b3ccd88cf127a305"},"headline":"Obviousness, Synergy, and Enablement in Biologic Formulations","datePublished":"2025-09-05T11:14:23+00:00","dateModified":"2025-09-05T11:17:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/"},"wordCount":1694,"commentCount":0,"publisher":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#organization"},"keywords":["Top News"],"articleSection":["Intellectual Property"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/","name":"Obviousness, Synergy, and Enablement in Biologic Formulations - Legal Service India - Articles","isPartOf":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#website"},"datePublished":"2025-09-05T11:14:23+00:00","dateModified":"2025-09-05T11:17:59+00:00","description":"Amgen vs Patent Office Madras HC ruling on romiplostim patent under Indian Patents Act, Sections 3(d), 3(e), 2(1)(ja) & 10(4).","breadcrumb":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/obviousness-synergy-and-enablement-in-biologic-formulations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/"},{"@type":"ListItem","position":2,"name":"Intellectual Property > Obviousness, Synergy, and Enablement in Biologic Formulations"}]},{"@type":"WebSite","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#website","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/","name":"Legal Service India - Law Articles","description":"Legal Service India - Law Article Directory is the oldest in India since 2000, with thousands of article written by lawyers, law Students and Scholars on all branches of law","publisher":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#organization","name":"Legal Service India","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/logo\/image\/","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2025\/06\/logo-circle-1.png","contentUrl":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-content\/uploads\/2025\/06\/logo-circle-1.png","width":105,"height":95,"caption":"Legal Service India"},"image":{"@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/legalservicesind","https:\/\/x.com\/legalserviceind","https:\/\/www.youtube.com\/@LegalServiceIndia-lsi"]},{"@type":"Person","@id":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/#\/schema\/person\/96ae33c2330691e5b3ccd88cf127a305","name":"ADVOCATE AJAY AMITABH SUMAN","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.gravatar.com\/avatar\/b894b0814afe1239db393e20da4b2e76?s=96&#038;r=g&#038;d=mm","url":"\/\/www.gravatar.com\/avatar\/b894b0814afe1239db393e20da4b2e76?s=96&#038;r=g&#038;d=mm","contentUrl":"\/\/www.gravatar.com\/avatar\/b894b0814afe1239db393e20da4b2e76?s=96&#038;r=g&#038;d=mm","caption":"ADVOCATE AJAY AMITABH SUMAN"},"description":"Professional and Literary Profile Mr. Ajay Amitabh Suman, Advocate, is an alumnus of the Campus Law Centre, University of Delhi, with over 20 years of experience in IP litigation before the Delhi High Court. He currently serves as a Patent and Trademark Attorney at United &amp; United, a leading intellectual property law firm. Deeply committed to legal scholarship, he has authored more than 900 articles on intellectual property law, published on major platforms including Legal Service India, Bar &amp; Bench, Live Law, SCC Online Blog, Legal Desire, SpicyIP, among others. Beyond his legal practice, he is also an accomplished writer and poet, with over 1,500 literary works and more than 20 books published in Hindi and English. His journey reflects a unique blend of legal advocacy and creative expression, inspired by a passion for justice, knowledge, and reform.","url":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/author\/ajayamitabhsuman\/"}]}},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/7985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/users\/56"}],"replies":[{"embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/comments?post=7985"}],"version-history":[{"count":0,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/posts\/7985\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/media?parent=7985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/categories?post=7985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.legalserviceindia.com\/Legal-Articles\/wp-json\/wp\/v2\/tags?post=7985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}